VYNE reports FY2022 net loss $23.2M; VYN201 Phase 1b in vitiligo dosing

VYNE Therapeutics Inc.

GAAP net loss of $23.2M for FY2022 vs $73.3M in 2021; adjusted net loss $18.9M.
Topline Phase 1b data for VYN201 (pan-BD BET inhibitor) in vitiligo expected mid-2023.
Positive preliminary Phase 1a safety data for VYN201; three doses selected for Phase 1b.
Regained Nasdaq minimum bid price compliance after 1-for-18 reverse stock split in Feb 2023.
VYN202 option agreement extended to April 2023; IND-enabling studies planned.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

VYNE Therapeutics Inc. reported financial results for year ended December 31, 2022.

Period: year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 9, 2023, VYNE Therapeutics Inc. issued a press release announcing its financial results for the year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

VYNE Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-007294

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.